Leaders of the Global Liquid Biopsy Revolution

As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD).

SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.

Biotechnology

Life Sciences

Pharmaceutical

Sysmex Inostics

Sysmex Inostics' headquarters in Baltimore, MD, United States

Shinichi Sato

Jonathan Craft

Yosuke Baba

Research and Scientific Development

Clinical and Laboratory Team

Project Management

Quality Management Team

Leadership Team

Sysmex Inostics

Org chart

Teams

Research and Scientific Development

Clinical and Laboratory Team

Project Management

Quality Management Team

Leadership Team

Offices

Similar companies